Cholesterol delivered to macrophages by oxidized low density lipoprotein is sequestered in lysosomes and fails to efflux normally.
Oxidized low density lipoprotein (LDL) has been found to exhibit numerous potentially atherogenic properties, including transformation of macrophages to foam cells. It is believed that high density lipoprotein (HDL) protects against atherosclerosis by removing excess cholesterol from cells of the artery wall, thereby retarding lipid accumulation by macrophages. In the present study, the relative rates of HDL-mediated cholesterol efflux were measured in murine resident peritoneal macrophages that had been loaded with acetylated LDL or oxidized LDL. Total cholesterol content of macrophages incubated for 24 h with either oxidized LDL or acetylated LDL was increased by 3-fold. However, there was no release of cholesterol to HDL from cells loaded with oxidized LDL under conditions in which cells loaded with acetylated LDL released about one-third of their total cholesterol to HDL. Even mild degrees of oxidation were associated with impairment of cholesterol efflux. Macrophages incubated with vortex-aggregated LDL also displayed impaired cholesterol efflux, but aggregation could not account for the entire effect of oxidized LDL. Resistance of apolipoprotein B (apoB) in oxidized LDL to lysosomal hydrolases and inactivation of hydrolases by aldehydes in oxidized LDL were also implicated. The subcellular distribution of cholesterol in oxidized LDL-loaded cells and acetylated LDL-loaded cells was investigated by density gradient fractionation, and this indicated that cholesterol derived from oxidized LDL accumulates within lysosomes. Thus impairment of cholesterol efflux in oxidized LDL-loaded macrophages appears to be due to lysosomal accumulation of oxidized LDL rather than to impaired transport of cholesterol from a cytosolic compartment to the plasma membrane.
Dhaliwal
B S
BS
Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada V5Z 3P1.
Steinbrecher
U P
UP
D000107:Acetylation; D000818:Animals; D001055:Apolipoproteins B / Q000378:metabolism; D001692:Biological Transport / Q000187:drug effects; D001894:Borohydrides / Q000494:pharmacology; D018929:Cell Culture Techniques; D002784:Cholesterol / Q000378:metabolism* / Q000493:pharmacokinetics; D019281:Dimerization; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000187:drug effects / Q000378:metabolism*; D008247:Lysosomes / Q000187:drug effects*; D008264:Macrophages / Q000378:metabolism* / Q000648:ultrastructure; D051379:Mice; D010084:Oxidation-Reduction; D013997:Time Factors; D014316:Tritium
D001055:Apolipoproteins B; D001894:Borohydrides; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D014316:Tritium; C025364:sodium borohydride; D002784:Cholesterol